Allogeneic Versus Autologous Stem-Cell Therapy - The author discusses potential manufacturing costs and commercialization challenges of allogeneic and autologous stem-cell therapy. - BioPharm

ADVERTISEMENT

Allogeneic Versus Autologous Stem-Cell Therapy
The author discusses potential manufacturing costs and commercialization challenges of allogeneic and autologous stem-cell therapy.


BioPharm International
Volume 25, Issue 7, pp. 36-40

CONCLUSION

At present, allogeneic stem-cell therapy appears to be the more commercially attractive option for companies to pursue, both in terms of its manufacturing costs and logistics as well as in terms of its business potential because it will in essence be available as an "off-the-shelf" product, meaning it could be used in both acute and chronic disease settings. Yet, for certain medical conditions, autologous therapy is likely to prove the only feasible therapeutic option and still support an acceptable pharmacoeconomic calculation.

In the coming years, greater regulatory guidance is likely to be published on the production of cell-based therapies, which may more clearly define how allogeneic and autologous therapies should be manufactured, thereby allowing a clearer picture to emerge about therapy production costs and logistics. The field of cell therapy manufacturing is also advancing swiftly, meaning that improved large-scale, automated manufacturing technologies can be expected, which should positively affect the cost and logistical difficulties underlying cell-based therapy production.

ACKNOWLEDGMENT

This paper is based on the author's thesis submitted for a Master's in Bioscience Enterprise degree at the Univ. of Cambridge. The author thanks Dr. Catherine Prescott and Dr. Ruth McKernan for their supervision and support.

Dr. Nafees N. Malik, MB, ChB, MPhil (Camb), CSci, is an external lecturer at the Institute of Biotechnology at the University of Cambridge,
.

REFERENCES

1. M. Körbling and Z. Estrov, N. Engl. J. Med. 349 (6), 570–582 (2003).

2. D. Srivastava and K.N. Ivey, Nature 441 (7097), 1097–1099 (2006).

3. C. Aguayo-Mazzucato and S. Bonner-Weir, Nat. Rev. Endocrinol. 6 (3), 139–148 (2010).

4. O. Lindvall and Z. Kokaia, J. Clin. Invest. 120 (1), 29–40 (2010).

5. R. McKernan, J. McNeish and D. Smith, Cell Stem-Cell 6 (6), 517–520 (2010).

6. C. Mason, Regen. Med. 2 (1), 11–18 (2007).

7. L. Jackson, D.R. Jones, P. Scotting and V. Sottile, J. Postgrad. Med. 53 (2), 121–127 (2007).

8. E. Fossett and W.S. Khan, Stem-Cells Int'l., Article ID 465259, 2012. doi:10.1155/2012/465259.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here